[CAS NO. 1607803-67-7] B I09
PRODUCTS SPECIFICATIONS [1607803-67-7]
DESCRIPTION [1607803-67-7]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 303.31 |
| Molecular Formula | C16H17NO5 |
| SMILES | OC1=CC=C(C2=C(CNCC2)C3=O)C(O3)=C1C4OCCCO4 |
1 Publications Citing Use of MCE
Summary
B I09 is an IRE-1 RNase inhibitor , with an IC 50 of 1230 nM.
IC50 & Target
IC50: 1230 nM (IRE-1 RNase) [1] .
In Vitro
B I09 is an IRE-1 RNase inhibitor, with an IC 50 of 1230 nM [1] . Treatment of CLL cells with this inhibitor (B I09) mimick XBP-1 deficiency, including upregulation of IRE-1 expression and compromised BCR signaling. B I09 is highly effective in inhibiting splicing of XBP1 mRNA in human WaC3 cells and the expression of XBP-1s in LPS stimulated B cells [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
B I09 has a halflife of approximately 1.5 hours and reaches its peak concentration of approximately 39 μM in mouse plasma serum 15 minutes after administration. Administration of B I09 to CLL tumor-bearing mice suppress leukemic progression by inducing apoptosis and do not cause systemic toxicity [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvent & Solubility
DMSO : 8.33 mg/mL ( 27.46 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.2970 mL | 16.4848 mL | 32.9696 mL |
| 5 mM | 0.6594 mL | 3.2970 mL | 6.5939 mL |
| 10 mM | 0.3297 mL | 1.6485 mL | 3.2970 mL |
-
1.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: 2.5 mg/mL (8.24 mM); Suspended solution; Need ultrasonic
References